Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + carboplatin + capecitabine
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A three-drug chemotherapy regimen combining the taxane docetaxel, the platinum agent carboplatin, and the oral fluoropyrimidine prodrug capecitabine. Docetaxel stabilizes microtubules and inhibits depolymerization to block mitosis; carboplatin forms DNA intra- and interstrand crosslinks to inhibit DNA replication and transcription; capecitabine is converted to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and incorporates into RNA and DNA, impairing nucleic acid synthesis. The combination has been studied primarily in advanced or metastatic esophagogastric cancers as a modification of docetaxel–platinum–fluoropyrimidine regimens, with varying schedules evaluated in phase I/II and a randomized phase II trial.
- Brand names
- TaxotereParaplatinXeloda
- Other names
- CTX
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)
Beyond the preview
Go deeper on docetaxel + carboplatin + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + carboplatin + capecitabine.